Citadel Advisors
LSBPW

Citadel Advisors’s LakeShore Biopharma Warrants LSBPW Stock Holding History

Citadel Advisors’s Portfolio LSBPW Stock Details LSBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-21,918
Closed -$1.12K – 15615
2024
Q1 		$1.12K Buy
+21,918
New +$1.22K ﹤0.01% 14176

Other funds holding LSBPW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
VAM
Valliance Asset Management Central, Hong Kong $122M AUM 362.1% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BP
BFAM Partners Northpoint, Hong Kong, Hong Kong $44K AUM 8.69% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
QGA
Q Global Advisors Fort Worth, Texas $113M AUM 20.91% 1-Year Est. Return

Citadel Advisors's LSBPW Position: Q2 2024 in Review

Citadel Advisors sold out of LakeShore Biopharma Warrants (LSBPW) in Q2 2024, closing a stake of 21,918 shares — an estimated $1.12K sold.

Citadel Advisors first reported a position in LSBPW in Q1 2024 and held it in 1 quarter. The position peaked at $1.12K in Q1 2024. 23 funds tracked by Wall St. Rank hold LSBPW as of Q2 2024.

  • Citadel Advisors reported no remaining LakeShore Biopharma Warrants position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 21,918 LakeShore Biopharma Warrants shares in Q2 2024, an estimated $1.12K.
  • Citadel Advisors first reported a position in LakeShore Biopharma Warrants in Q1 2024 and held it in 1 quarter.
  • Citadel Advisors's LakeShore Biopharma Warrants position peaked at $1.12K in Q1 2024.
  • 23 funds tracked by Wall St. Rank held LakeShore Biopharma Warrants as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.